Humoral and Cellular Responses to a Delayed Fourth SARS-CoV-2 mRNA-Based Vaccine in Weak Responders to 3 Doses Kidney Transplant Recipients

Article Surgery

Anti-SARS-CoV-2 spike protein and neutralizing antibodies at 1 and 3 months after three doses of SARS-CoV-2 vaccine in a large cohort of solid organ transplant patients

Nassim Kamar et al.

Summary: The immunogenicity of the SARS-CoV-2 vaccine was enhanced by a third dose. A retrospective study on solid organ transplant patients found that two-thirds of them developed anti-SARS-CoV-2 antibodies after three doses, but one-third remained weak or non-protected. Antibody concentrations and protection levels decreased between 1 and 3 months after vaccination.

AMERICAN JOURNAL OF TRANSPLANTATION (2022)

Add to Collection

Article Surgery

SARS-CoV-2-specific humoral and cell-mediated immune responses after immunization with inactivated COVID-19 vaccine in kidney transplant recipients (CVIM 1 study)

Jackrapong Bruminhent et al.

Summary: Solid organ transplant recipients who received inactivated SARS-CoV-2 vaccination showed weak humoral immunity but comparable cell-mediated immunity responses compared to immunocompetent individuals.

AMERICAN JOURNAL OF TRANSPLANTATION (2022)

Add to Collection

Letter Medicine, General & Internal

Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series

Sophie Caillard et al.

ANNALS OF INTERNAL MEDICINE (2022)

Add to Collection

Article Biochemistry & Molecular Biology

The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic

Markus Hoffmann et al.

Summary: The Omicron variant of SARS-CoV-2 is spreading rapidly and shows resistance to most therapeutic antibodies. It also evades neutralization by antibodies induced by infection or vaccination more efficiently than the Delta variant. This suggests that therapeutic antibodies may not be effective against the Omicron variant, and double vaccination with BNT162b2 may not provide adequate protection against severe disease caused by this variant.

CELL (2022)

Add to Collection

Letter Medicine, General & Internal

Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals

Brian Grunau et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

Add to Collection

Letter Infectious Diseases

Antibody titers and breakthrough infections with Omicron SARS-CoV-2

Chloe Dimeglio et al.

JOURNAL OF INFECTION (2022)

Add to Collection

Article Microbiology

Evaluation of Three Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

Sabine Chapuy-Regaud et al.

Summary: Three commercially available assays for SARS-CoV-2 antibodies were evaluated with varying sensitivity for different stages of infection. The assays showed correlation with neutralizing antibody titers, but discrepancies were observed in certain scenarios.

MICROBIOLOGY SPECTRUM (2021)

Add to Collection

Letter Medicine, General & Internal

Assessment of 4 Doses of SARS-CoV-2 Messenger RNA-Based Vaccine in Recipients of a Solid Organ Transplant

Nassim Kamar et al.

JAMA NETWORK OPEN (2021)

Add to Collection

Editorial Material Virology

Clinical performance of a rapid test compared to a microplate test to detect total anti SARS-CoV-2 antibodies directed to the spike protein

Florence Abravanel et al.

JOURNAL OF CLINICAL VIROLOGY (2020)

Add to Collection

Humoral and Cellular Responses to a Delayed Fourth SARS-CoV-2 mRNA-Based Vaccine in Weak Responders to 3 Doses Kidney Transplant Recipients

Related references

Export Citation

Share Paper